{"content":"<li class=\"n-box-item date-title\" data-end=\"1501905599\" data-start=\"1501819200\" data-txt=\"Monday, December 23, 2019\">Friday, August  4, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3286062\" data-ts=\"1501880871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286062-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/COL' title='Rockwell Collins, Inc.'>COL</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/TGS' title='Transportadora de Gas del Sur'>TGS</a> <font color='green'>+4%</font>.<a href='https://seekingalpha.com/symbol/PRO' title='PROS Holdings, Inc.'>PRO</a> <font color='green'>+2%</font>. <a href='https://seekingalpha.com/symbol/BL' title='BlackLine'>BL</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/VIAV' title='Viavi Solutions Inc.'>VIAV</a> <font color='green'>+4%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GNMK' title='GenMark Diagnostics, Inc.'>GNMK</a> <font color='red'>-3%</font>. <a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a> <font color='red'>-2%</font>. <a href='https://seekingalpha.com/symbol/HBI' title='Hanesbrands Inc.'>HBI</a> <font color='red'>-4%</font>. <a href='https://seekingalpha.com/symbol/SON' title='Sonoco Products Co.'>SON</a> <font color='red'>-4%</font>. <a href='https://seekingalpha.com/symbol/NSA' title='National Storage Affiliates Trust'>NSA</a> <font color='red'>-4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286062\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$COL $TGS $PRO - After Hours Gainers / Losers https://seekingalpha.com/news/3286062-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3286062-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286056\" data-ts=\"1501879055\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COL\" target=\"_blank\">COL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286056-rockwell-collinsplus-9_5-on-report-utx-looking-buyout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rockwell Collins +9.5% on report UTX looking at buyout</a></h4><ul>   <li>Rockwell Collins (NYSE:<a href='https://seekingalpha.com/symbol/COL' title='Rockwell Collins, Inc.'>COL</a>) has <font color='green'>jumped 9.5%</font> in after-hours trade after a Bloomberg report notes United Technologies (NYSE:<a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a>) is weighing a deal for the company.</li>    <li><a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a> <font color='green'>gained 0.3%</font> today and is flat in after-hours trading at the moment.</li>    <li><b>Updated:</b> It's not clear whether the two companies are actively in talks, Bloomberg says.</li>    <li>Rockwell Collins, the supplier of aircraft cabin equipment, has a market cap of $19B; it closed today at $119 and is up to $126.50 as of 4:51 p.m. Aircraft engine maker United Technologies is worth about $97B.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3286056\" data-linked=\"Rockwell Collins +9.5% on report UTX looking at buyout\" data-tweet=\"$COL $COL $UTX - Rockwell Collins +9.5% on report UTX looking at buyout https://seekingalpha.com/news/3286056-rockwell-collinsplus-9_5-on-report-utx-looking-buyout?source=tweet\" data-url=\"https://seekingalpha.com/news/3286056-rockwell-collinsplus-9_5-on-report-utx-looking-buyout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286054\" data-ts=\"1501878810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USM\" target=\"_blank\">USM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286054-u-s-cellularplus-2_7-on-added-customers-revenue-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Cellular +2.7% on added customers, revenue beat</a></h4><ul>   <li>U.S. Cellular (NYSE:<a href='https://seekingalpha.com/symbol/USM' title='United States Cellular Corporation'>USM</a>) <font color='green'>rose 2.7%</font> after <a href=\"https://seekingalpha.com/news/3285905-united-states-cellular-misses-0_03-beats-revenue\" target=\"_blank\">Q2 earnings</a> where profits fell short but revenues declined less than expected.</li>    <li>Net postpaid subs reversed course with a gain of 23,000, bringing the total to 4.478M. In prepaid service, the company added a net 3,000 customers to hit 484,000.</li>    <li>Revenue breakout: Service, $740M (down 4%); Equipment sales, $223M (up 2%).</li>    <li>Postpaid ARPU fell to $44.60, down from a year-ago $47.37 and last quarter's $45.42. Churn rate fell to 1.13% from the year-ago 1.20% and last quarter's 1.29%.</li>    <li>Prepaid ARPU fell as well, to $33.52 from a year-ago $34.58 and last quarter's $33.66. Churn rate was 4.93%; a year ago it was 4.86%, and last quarter had risen to 5.69%.</li>    <li>It's reiterating full-year guidance: for operating revenues of $3.8B-$4B (vs. consensus for $3.85B), adjusted EBITDA of $700M-$800M (above expectations for $649.9M) and capex of about $500M.</li>    <li><a href=\"https://seekingalpha.com/pr/16907198-u-s-cellular-reports-second-quarter-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3286054\" data-linked=\"U.S. Cellular +2.7% on added customers, revenue beat\" data-tweet=\"$USM - U.S. Cellular +2.7% on added customers, revenue beat https://seekingalpha.com/news/3286054-u-s-cellularplus-2_7-on-added-customers-revenue-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3286054-u-s-cellularplus-2_7-on-added-customers-revenue-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286036\" data-ts=\"1501876404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMY-OLD\" target=\"_blank\">IMMY-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286036-imprimis-down-18-of-fda-inquiry-compounded-product\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Imprimis down 18% of FDA inquiry into compounded product</a></h4><ul><li>Thinly traded nano cap Imprimis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IMMY-OLD' title='Imprimis Pharmaceuticals, Inc.'>IMMY-OLD</a> <font color='red'>-18%</font>) slumps on double normal volume, albeit on turnover of only 250K shares, in apparent response to the <a href=\"https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm570192.htm\" target=\"_blank\">news </a>that the FDA is looking into two serious adverse events related to its curcumin emulsion for injection product, one involving cardiac arrest.</li><li>Reportedly, the compounded product lacked a label warning about hypersensitivity reactions associated with ungraded PEG 40 castor oil, an ingredient not suitable for human consumption or therapeutic use that may contain impurities. Also, the safety of the intravenous route of administration has not been established, nor has its effectiveness in treating eczema or thrombocytopenia.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286036\" data-linked=\"Imprimis down 18% of FDA inquiry into compounded product\" data-tweet=\"$IMMY-OLD - Imprimis down 18% of FDA inquiry into compounded product https://seekingalpha.com/news/3286036-imprimis-down-18-of-fda-inquiry-compounded-product?source=tweet\" data-url=\"https://seekingalpha.com/news/3286036-imprimis-down-18-of-fda-inquiry-compounded-product\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286035\" data-ts=\"1501876020\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTZ\" target=\"_blank\">HTZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286035-jpmorgan-turns-sentiment-on-avis-and-hertz\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan turns sentiment on Avis and Hertz</a></h4><ul>     <li>Hertz Global (<a href='https://seekingalpha.com/symbol/HTZ' title='Hertz Global Holdings, Inc.'>HTZ</a> <font color='green'>+10.1%</font>) and Avis Budget Group (<a href='https://seekingalpha.com/symbol/CAR' title='Avis Budget Group, Inc.'>CAR</a> <font color='green'>+4.1%</font>) break higher after JPMorgan delivers some sell-side relief on the car rental stocks.</li>     <li>\"Margin progression and strong free cash flow delivered by Avis historically, while contending with industry headwinds, speak to solid execution by an experienced management team, in our view,\" writes&nbsp;Analyst Samik Chatterjee.</li><li>Chatterjee thinks both Hertz and Avis have been hit too hard by investors concerns over sector headwinds.</li><li>JP rates Hertz at Neutral with a $15 PT. Avis catches an Overweight rating and $39 PT. Both companies report earnings next week.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286035\" data-linked=\"JPMorgan turns sentiment on Avis and Hertz\" data-tweet=\"$HTZ $HTZ $CAR - JPMorgan turns sentiment on Avis and Hertz https://seekingalpha.com/news/3286035-jpmorgan-turns-sentiment-on-avis-and-hertz?source=tweet\" data-url=\"https://seekingalpha.com/news/3286035-jpmorgan-turns-sentiment-on-avis-and-hertz\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286032\" data-ts=\"1501874849\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADDYY\" target=\"_blank\">ADDYY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286032-adidas-steps-up-game\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adidas steps up its game</a></h4><ul>     <li>Adidas (<a href='https://seekingalpha.com/symbol/ADDYY' title='adidas AG ADR'>OTCQX:ADDYY</a>) posted another quarter that showed just how competitive the company is with Nike (<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='red'>-0.6%</font>) and Under Armour (NYSE:<a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a>).</li>     <li>The company knocked out Q2 sales growth of 20% and increased full-year revenue growth guidance to a range of +17% to +19% vs. +12% to +14% prior. During the summer quarter, Adidas tallied revenue growth of 26% in North America.</li>     <li>Cowen keeps it simple in <a href=\"http://www.barrons.com/articles/nike-darn-you-adidas-1501869526\" target=\"_blank\">assessing</a> Adidas and it peers.</li>     <li>\"Consensus is underestimating sales and margin expansion potential through 2018 as product cycle heats up. UAA guidance for big acceleration in Q4 remains at risk. Remains a top pick,\" reads the firm's note.</li>     <li>Across the industry, Adidas has impressed with its on-trend fashion mix. \"Adidas remains the hottest brand in the U.S. active market,\" <a href=\"https://www.benzinga.com/news/earnings/17/08/9874962/adidas-continues-to-outpace-the-competition-brand-grew-33-in-north-ameri\" target=\"_blank\">observes</a> NPD Group's Matt Powell.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3285036-adidas-ag-reports-q2-results\" target=\"_blank\">adidas AG reports Q2 results</a> (Aug. 3)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286032\" data-linked=\"Adidas steps up its game\" data-tweet=\"$ADDYY $ADDYY $NKE - Adidas steps up its game https://seekingalpha.com/news/3286032-adidas-steps-up-game?source=tweet\" data-url=\"https://seekingalpha.com/news/3286032-adidas-steps-up-game\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286031\" data-ts=\"1501871548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WFC\" target=\"_blank\">WFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286031-wells-fargo-drops-filing-shows-find-many-fake-accounts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo drops as filing shows it could find many more fake accounts</a></h4><ul>   <li>Wells Fargo (NYSE:<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Co.'>WFC</a>) has taken a downturn, <font color='red'>-1.1%</font> now after a positive morning, following the release of a <a href=\"https://www.sec.gov/Archives/edgar/data/72971/000007297117000397/wfc-06302017x10q.htm\" target=\"_blank\">10-Q filing</a> where it says a wider look into its sales practice issues could reveal a \"significant increase in the identified number of potentially unauthorized accounts.\"</li>    <li>That might mean legal costs exceeding its set-asides, it adds. But \"we do not expect any incremental customer remediation costs as a result of these efforts to have a significant financial impact on the company.\"</li>    <li>The company is adding three years to the initial review period of about four years (May 2011 to mid-2015). It expanded the review to cover the consent order period of January 2011 through September 2016, and is voluntarily reviewing accounts from 2009-2010.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286031\" data-linked=\"Wells Fargo drops as filing shows it could find many more fake accounts\" data-tweet=\"$WFC - Wells Fargo drops as filing shows it could find many more fake accounts https://seekingalpha.com/news/3286031-wells-fargo-drops-filing-shows-find-many-fake-accounts?source=tweet\" data-url=\"https://seekingalpha.com/news/3286031-wells-fargo-drops-filing-shows-find-many-fake-accounts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286028\" data-ts=\"1501870013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286028-financials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 2:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ECPG' title='Encore Capital Group Inc'>ECPG</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a> <font color='green'>+11%</font>.<a href='https://seekingalpha.com/symbol/RMAX' title='RE/MAX Holdings, Inc.'>RMAX</a> <font color='green'>+11%</font>. RAS <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/HCC' title='Warrior Met Coal'>HCC</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BRG' title='Bluerock Residential Growth REIT, Inc.'>BRG</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286028\" data-linked=\"Financials - Top 5 Gainers / Losers as of 2:00 PM\" data-tweet=\"$ECPG $LEJU $RMAX - Financials - Top 5 Gainers / Losers as of 2:00 PM https://seekingalpha.com/news/3286028-financials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3286028-financials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286027\" data-ts=\"1501870007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286027-snap-pares-gains-on-report-google-is-working-on-discover-like-feature\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap pares gains on report Google is working on Discover-like feature</a></h4><ul>   <li>Live by the Google, <i>dip</i> by the Google? A day after moving higher based on reports that Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='green'>+0.3%</font>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='green'>+0.4%</font>) had <a href=\"https://seekingalpha.com/news/3285432-snap-shares-rumors-google-interest\" target=\"_blank\">expressed interest in buying Snap</a> (<a href=\"http://seekingalpha.com/symbol/SNAP\" target=\"_blank\">SNAP</a> <font color='green'>+3.6%</font>) for up to $30B, Snap shares are paring today's gains a bit after a <i>Wall Street Journal</i> report that Google's <a href=\"https://www.wsj.com/articles/google-is-developing-technology-for-snapchat-like-media-content-1501868688\" target=\"_blank\">building similar media technology</a>.</li>    <li>Google's \"Stamp\" would be built on its AMP speedy mobile Web pages, and let publishers create Snapchat Discover-like content with a heavy visual component (\"Stamp\" = Stories plus AMP).</li>    <li>That would mean swipe-able slides with text, photos and video a la Snapchat.</li>    <li>&ldquo;Ever since the beginning of AMP we&rsquo;ve constantly collaborated with publishers, and are working on many new features,&rdquo; Google says in response.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286027\" data-linked=\"Snap pares gains on report Google is working on Discover-like feature\" data-tweet=\"$GOOG $GOOG $GOOGL - Snap pares gains on report Google is working on Discover-like feature https://seekingalpha.com/news/3286027-snap-pares-gains-on-report-google-is-working-on-discover-like-feature?source=tweet\" data-url=\"https://seekingalpha.com/news/3286027-snap-pares-gains-on-report-google-is-working-on-discover-like-feature\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286026\" data-ts=\"1501869642\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286026-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/TREC' title='Trecora Resources'>TREC</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PACD' title='Pacific Drilling SA'>PACD</a> <font color='red'>-30%</font>. <a href='https://seekingalpha.com/symbol/AG' title='First Majestic Silver Corp.'>AG</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/BIOA' title='BioAmber'>OTC:BIOA</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/APLP' title='Archrock Partners, L.P.'>APLP</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='red'>-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286026\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$MCF $EMES $FMSA - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3286026-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3286026-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286025\" data-ts=\"1501869443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANET\" target=\"_blank\">ANET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286025-arista-networksplus-20_8-analysts-praise-blow-out-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arista Networks +20.8% as analysts praise &#39;blow-out&#39; quarter</a></h4><ul>   <li>Arista Networks (NYSE:<a href='https://seekingalpha.com/symbol/ANET' title='Arista Networks, Inc.'>ANET</a>) is among today's top tech movers, <font color='green'>up 20.8%</font> to a new all-time high after <a href=\"https://seekingalpha.com/news/3285724-arista-networks-jumps-14-percent-healthy-cloud-driven-q2-beat\" target=\"_blank\">solidly beating expectations with its Q2</a> and seeing analyst upgrades today.</li>    <li>High price targets come from Barclays and FBN, at $200, implying 15% upside from a price already up more than 20% today.</li>    <li>FBN's Shebly Seyrafi says this is just the latest of many \"blow-out\" reports and <a href=\"http://www.barrons.com/articles/arista-soars-20-bulls-laud-business-on-fire-superb-execution-1501866978\" target=\"_blank\">praises a growing product line</a>: \"With the May 2017 introduction of its R2 Series Leaf and Spine, which drive cloud-scale routing with R2 Series line cards for existing Spine, new Leaf switches, and a new 16-slot Universal Spine switch, ANET is well-positioned to sell more solutions to the cloud vertical going forward.\"</li>    <li>The business is \"on fire\" with multiple tailwinds, says William Blair, which upgraded to Outperform. It's getting unlikely that the firm will get the pullback it wanted before getting more vocal about the stock, says analyst Jason Ader.</li>    <li>JPMorgan's Rod Hall raised the price target to $186 from $144: \"It is hard to overstate how well this team continues to execute in our opinion,\" he says, pointing to a fight with Cisco that's \"now largely in the rearview mirror with patents in the latest case being declared invalid by PTAB.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286025\" data-linked=\"Arista Networks +20.8% as analysts praise &#39;blow-out&#39; quarter\" data-tweet=\"$ANET - Arista Networks +20.8% as analysts praise &#39;blow-out&#39; quarter https://seekingalpha.com/news/3286025-arista-networksplus-20_8-analysts-praise-blow-out-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3286025-arista-networksplus-20_8-analysts-praise-blow-out-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286024\" data-ts=\"1501868474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRN\" target=\"_blank\">APRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286024-blue-apron-slides-after-announcing-potential-job-cuts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Apron slides after announcing potential job cuts</a></h4><ul> <li>The bumpy post-IPO ride continues for Blue Apron (<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a> <font color='red'>-4.5%</font>) after the company opts to close a facility in New Jersey. The company anticipates that about 1,270 workers will decide not to transfer to a new location, according to a <a href=\"http://lwd.state.nj.us/WorkForceDirectory/warn.jsp?printacrossID=1&amp;StartDate=08/01/2017&amp;EndDate=08/31/2017&amp;DisplayDate=August%202017\" target=\"_blank\">filing</a> with the New Jersey Department of Labor.</li> <li>Shares of Blue Apron hit a new low if $5.83 earlier today. Originally, Blue Apron set a pricing range of $15 to $17 on the stock.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3286024\" data-linked=\"Blue Apron slides after announcing potential job cuts\" data-tweet=\"$APRN - Blue Apron slides after announcing potential job cuts https://seekingalpha.com/news/3286024-blue-apron-slides-after-announcing-potential-job-cuts?source=tweet\" data-url=\"https://seekingalpha.com/news/3286024-blue-apron-slides-after-announcing-potential-job-cuts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286020\" data-ts=\"1501865931\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHAK\" target=\"_blank\">SHAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286020-shake-shack-execs-not-sweating-comp-sales-decline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shake Shack execs not sweating comp sales decline</a></h4><ul> <li>Shake Shack (NYSE:<a href='https://seekingalpha.com/symbol/SHAK' title='Shake Shack'>SHAK</a>) is <font color='red'>down 4.63%</font> on heavy volume after Q2 results disappoint.</li> <li>The chain reported a 1.8% drop in comparable sales, a metric that Shake Shack execs think needs some context to be understood.</li> <li>The 37 Shacks used for the comparable basis represent less than half of U.S. stores, they note. This means weather glitches or other seasonal factors can have an oversized impact.</li> <li><a href=\"https://seekingalpha.com/article/4094755-shake-shacks-shak-ceo-randall-garutti-q2-2017-results-earnings-call-transcript?part=single\" target=\"_blank\">Shake Shack earnings call transcript</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3285543-revenue-guidance-light-shake-shack\" target=\"_blank\">Revenue guidance light from Shake Shack</a> (Aug. 3)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286020\" data-linked=\"Shake Shack execs not sweating comp sales decline\" data-tweet=\"$SHAK - Shake Shack execs not sweating comp sales decline https://seekingalpha.com/news/3286020-shake-shack-execs-not-sweating-comp-sales-decline?source=tweet\" data-url=\"https://seekingalpha.com/news/3286020-shake-shack-execs-not-sweating-comp-sales-decline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286019\" data-ts=\"1501865911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YELP\" target=\"_blank\">YELP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286019-yelpplus-27_5-analysts-boost-targets-following-eat24-deal-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yelp +27.5% as analysts boost targets following Eat24 deal, earnings</a></h4><ul>   <li>Yelp (NYSE:<a href='https://seekingalpha.com/symbol/YELP' title='Yelp'>YELP</a>) is building even on <a href=\"https://seekingalpha.com/news/3285631-yelp-19-percent-double-digit-q2-gains-eat24-sale\" target=\"_blank\">strong postmarket moves</a> from last night, <font color='green'>up 27.5%</font> and back to its highest point in six months, as analysts react to its <a href=\"https://seekingalpha.com/news/3285495-grubhub-paying-287_5m-eat24-partnering-yelp\" target=\"_blank\">divestiture of Eat24</a> and a Q2 beat-and-raise.</li>    <li>A bullish price target comes from MKM, which raised to $48 from $27 (implying 17%&nbsp;upside from today's jacked-up price) and upgrades to Buy. Eat24 is selling for more than twice what Yelp paid, and it gets \"much higher transaction volume than YELP could drive on its own\" in the deal.</li>    <li>Needham reiterated its Buy and <a href=\"https://www.streetinsider.com/Analyst+Comments/Yelp+%28YELP%29+PT+Raised+to+%2443+at+Needham+%26+Company/13169093.html\" target=\"_blank\">raised its price target</a> to $43 from $30. The Eat24 sale should reduce costs and drive activity on the platform, says analyst Kerry Rice. The company can deliver 20% revenue growth and increased profits with \"several revenue growth levers to still pull, including improvements in retention, monetization, sales productivity, as well as ongoing growth in Self-Service and National advertising and marketing optimization.\"</li>    <li>Morgan Stanley's staying Neutral but says the Eat24 sale should benefit monetization considering 80% of Yelp users still don't know you can order food on the platform, Brian Nowak says: Cash flow per order should get better, restaurant selection will improve by 88% (~75k restaurants at GRUB vs ~40k at Yelp previously), and YELP will be able to invest more in its core business and customer acquisition.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286019\" data-linked=\"Yelp +27.5% as analysts boost targets following Eat24 deal, earnings\" data-tweet=\"$YELP - Yelp +27.5% as analysts boost targets following Eat24 deal, earnings https://seekingalpha.com/news/3286019-yelpplus-27_5-analysts-boost-targets-following-eat24-deal-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3286019-yelpplus-27_5-analysts-boost-targets-following-eat24-deal-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286017\" data-ts=\"1501865280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286017-spectrum-pharma-q2-beat-propels-shares-up-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spectrum Pharma Q2 beat propels shares, up 21%</a></h4><ul><li>Spectrum Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+20.9%</font>) is up on more than double normal volume after it <a href=\"https://seekingalpha.com/pr/16906608-spectrum-pharmaceuticals-reports-second-quarter-2017-financial-results-pipeline-update\" target=\"_blank\">posted </a>better-than-expected Q2 results.</li><li>Revenues were $34.3M (+1.2%), including product sales of $31.2M (+1.0%). Net loss narrowed almost 16% to ($20.5M).</li><li>BLA filing on tap for next year for neutropenia drug ROLONTIS (eflapegrastim).</li><li>Interim data from Phase 2 study of poziotinib in certain patients with non-small cell lung cancer expected before year-end. Another trial is being initiated for the indication in order to speed up development.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285513-spectrum-pharmaceuticals-beats-0_16-beats-revenue\" target=\"_blank\">Spectrum Pharmaceuticals beats by $0.16, beats on revenue</a> (Aug. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3286017\" data-linked=\"Spectrum Pharma Q2 beat propels shares, up 21%\" data-tweet=\"$SPPI - Spectrum Pharma Q2 beat propels shares, up 21% https://seekingalpha.com/news/3286017-spectrum-pharma-q2-beat-propels-shares-up-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3286017-spectrum-pharma-q2-beat-propels-shares-up-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286008\" data-ts=\"1501862606\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMNP\" target=\"_blank\">IMNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286008-immune-pharmas-strategic-plan-and-planned-cytovia-spinout-fail-to-stem-wave-of-selling-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immune Pharma&#39;s strategic plan and planned Cytovia spinout fail to stem the wave of selling; shares down 21%</a></h4><ul><li>Thinly traded nano cap Immune Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a> <font color='red'>-20.5%</font>) continues its slide on almost six times normal volume. Shares have lost 55% of their value in a month.</li><li>In a <a href=\"https://seekingalpha.com/pr/16907424-immune-pharmaceuticals-inc-issues-letter-shareholders\" target=\"_blank\">letter to shareholders</a> this morning, interim CEO Elliot Maza outlined the company's strategy, including the planned spinoff of Cytovia which will focus on developing cancer drug CEPLENE (histamine dihydrochoride).</li><li>Immune will continue its focus on lead asset bertilimumab, in Phase 2 development for bullous pemphigoid and ulcerative colitis.</li><li>The company plans to hire a new chief medical officer to lead its development efforts.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279510-immune-pharma-considering-pro-rata-share-distribution-shareholders-spin-cytovia\" target=\"_blank\">Immune Pharma considering pro rata share distribution to shareholders to spin out Cytovia</a> (July 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3286008\" data-linked=\"Immune Pharma&#39;s strategic plan and planned Cytovia spinout fail to stem the wave of selling; shares down 21%\" data-tweet=\"$IMNP $IMNPQ - Immune Pharma&#39;s strategic plan and planned Cytovia spinout fail to stem the wave of selling; shares down 21% https://seekingalpha.com/news/3286008-immune-pharmas-strategic-plan-and-planned-cytovia-spinout-fail-to-stem-wave-of-selling-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3286008-immune-pharmas-strategic-plan-and-planned-cytovia-spinout-fail-to-stem-wave-of-selling-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286009\" data-ts=\"1501862518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286009-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/ELY' title='Callaway Golf Company'>ELY</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/SGOC' title='SGOCO Techn'>SGOC</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/BGS' title='B&G Foods, Inc.'>BGS</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LCII' title='LCI Industries'>LCII</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/UEIC' title='Universal Electronics Inc.'>UEIC</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286009\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$GPRO $ELY $ANFI - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3286009-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3286009-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286007\" data-ts=\"1501860583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BNED\" target=\"_blank\">BNED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286007-barnes-noble-education-acquires-student-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barnes &amp; Noble Education acquires Student Brands</a></h4><ul>          <li>Barnes &amp; Noble Education (<a href='https://seekingalpha.com/symbol/BNED' title='Barnes & Noble Education, Inc'>BNED</a> <font color='green'>+2.5%</font>) completes the $58.5M&nbsp;acquisition of Student Brands.</li>     <li>Student       Brands utilizes deep data analytics and artificial intelligence to drive       its proprietary content management system, the Content Brain.</li>     <li>Barnes &amp; Noble Education utilized cash on hand and availability under its current       credit facility to finance the acquisition.</li><li>Student Brands is expected       to contribute over $10M&nbsp;of EBITDA to BNED&rsquo;s consolidated       operation results over the next twelve months.</li><li>The company says the acquisition will be accretive to its EBITDA, net income and cash flow in FY18.</li>     <li>BNED is <font color='green'>+2.11%</font>  to $7.25.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16907367-barnes-and-noble-education-acquires-student-brands\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3286007\" data-linked=\"Barnes &amp; Noble Education acquires Student Brands\" data-tweet=\"$BNED - Barnes &amp; Noble Education acquires Student Brands https://seekingalpha.com/news/3286007-barnes-noble-education-acquires-student-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3286007-barnes-noble-education-acquires-student-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286006\" data-ts=\"1501860481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMER\" target=\"_blank\">OMER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286006-omeros-oms721-orphan-drug-in-u-s-for-iga-nephropathy-shares-ahead-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omeros&#39; OMS721 an Orphan Drug in U.S. for IgA nephropathy; shares ahead 3%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16907462-fda-grants-orphan-drug-designation-omeros-oms721-treatment-iga-nephropathy\" target=\"_blank\">designates </a>Omeros' (<a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='green'>+2.7%</font>) lead candidate OMS721 an Orphan Drug for the treatment of a kidney disorder called IgA nephropathy, also known as <a href=\"http://www.mayoclinic.org/diseases-conditions/iga-nephropathy/home/ovc-20199316\" target=\"_blank\">Berger's disease</a>, in which the immunoglobulin IgA lodges in the kidneys. The slowly progressive disorder produces inflammation which compromises kidneys' function. About 40% of sufferers eventually develop end-stage renal disease. OMS721 also has Breakthrough Therapy status for the condition.</li><li>Phase 3-stage OMS721 binds to an enzyme called mannan-binding lectin-associated serine protease-2 (<a href=\"http://www.omeros.com/pipeline/masp.htm\" target=\"_blank\">MASP-2</a>) which plays a key role in the lectin pathway of the complement system, which is believed to contribute to significant tissue injury.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3273226-omeros-oms721-breakthrough-therapy-kidney-disorders-shares-ahead-10-percent\" target=\"_blank\">Omeros' OMS721 a Breakthrough Therapy for kidney disorders; shares ahead 10%</a> (June 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3286006\" data-linked=\"Omeros&#39; OMS721 an Orphan Drug in U.S. for IgA nephropathy; shares ahead 3%\" data-tweet=\"$OMER - Omeros&#39; OMS721 an Orphan Drug in U.S. for IgA nephropathy; shares ahead 3% https://seekingalpha.com/news/3286006-omeros-oms721-orphan-drug-in-u-s-for-iga-nephropathy-shares-ahead-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3286006-omeros-oms721-orphan-drug-in-u-s-for-iga-nephropathy-shares-ahead-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286000\" data-ts=\"1501859142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOOT\" target=\"_blank\">BOOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286000-boot-barn-rallies-after-baird-nod\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boot Barn rallies after Baird nod</a></h4><ul> <li>Boot Barn (NASDAQ:<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a>) extends on its <a href=\"https://www.streetinsider.com/Analyst+Comments/Baird+Upgrades+Boot+Barn+%28BOOT%29+to+Outperform/13168866.html\" target=\"_blank\">post-earnings rally</a> with a <font color='green'>7.84% gain</font>.</li> <li>Investors are taking note of an upgrade on Boot Barn from Baird to Outperform from Neutral.</li> <li>\"Near term, each point of comps improvement vs. our ~1.5% assumption for the next 12 months could contribute a mid-to-high single-digit percentage to annual EPS (modeling F2018 EPS +10% ex-53rd week),\" writes analysts Jonathan Kemp. \"Longer term, we do not believe BOOT is receiving credit for potential to accelerate unit growth to +10% which could drive strong +double-digit EPS gains,\" he adds.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283996-boot-barn-reports-q1-results\" target=\"_blank\">Boot Barn reports Q1 results</a> (Aug. 1)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3284464-shorts-scramble-boot-barn-posts-positive-store-sales-growth\" target=\"_blank\">Shorts scramble after Boot Barn posts positive same-store sales growth</a> (Aug. 2)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286000\" data-linked=\"Boot Barn rallies after Baird nod\" data-tweet=\"$BOOT - Boot Barn rallies after Baird nod https://seekingalpha.com/news/3286000-boot-barn-rallies-after-baird-nod?source=tweet\" data-url=\"https://seekingalpha.com/news/3286000-boot-barn-rallies-after-baird-nod\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285995\" data-ts=\"1501859086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEZS\" target=\"_blank\">AEZS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285995-aeterna-zentaris-goes-after-former-execs-over-alleged-scheme-to-control-company-shares-up-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aeterna Zentaris goes after former execs over alleged scheme to control company; shares up 14%</a></h4><ul><li>Nano cap Aeterna Zentaris (<a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+14%</font>) has rallied&nbsp;<font color='green'>40%</font>&nbsp;the past two days amidst the company's <a href=\"https://seekingalpha.com/pr/16906412-aeterna-zentaris-commences-legal-action-david-dodd-philip-theodore\" target=\"_blank\">legal tussle</a> with former CEO David Dodd and former General Counsel Philip Theodore over their attempts to seize control of the board and the U.S. rights to lead product Macrilen via a secret plan called \"Project Rescue\" they formulated with activist investor Graeme Roustan.</li><li>The company has filed a claim in a superior court seeking an injunction barring the two men from continuing to use the company's confidential information without authorization and from mounting a proxy fight.</li><li>Mr. Dodd was axed on July 20 for cause followed by Mr. Theodore's termination on July 28.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280148-aeterna-zentaris-names-new-ceo-will-evaluate-strategic-alternatives\" target=\"_blank\">AEterna Zentaris names new CEO, will evaluate strategic alternatives</a> (July 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3285995\" data-linked=\"Aeterna Zentaris goes after former execs over alleged scheme to control company; shares up 14%\" data-tweet=\"$AEZS - Aeterna Zentaris goes after former execs over alleged scheme to control company; shares up 14% https://seekingalpha.com/news/3285995-aeterna-zentaris-goes-after-former-execs-over-alleged-scheme-to-control-company-shares-up-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3285995-aeterna-zentaris-goes-after-former-execs-over-alleged-scheme-to-control-company-shares-up-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285986\" data-ts=\"1501859005\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285986-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/CFMS' title='ConforMIS'>CFMS</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/OVAS-OLD' title='OvaScience, Inc.'>OVAS-OLD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ABIO' title='ARCA biopharma, Inc.'>ABIO</a> <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3285986\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$SPPI $PDLI $CARA - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3285986-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3285986-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285990\" data-ts=\"1501856157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWL\" target=\"_blank\">NWL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285990-on-newell-brands-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Newell Brands&#39; Q2</a></h4><ul>     <li>Newell Brands (<a href='https://seekingalpha.com/symbol/NWL' title='Newell Brands Inc.'>NWL</a> <font color='red'>-2.6%</font>)&nbsp;reports core sales growth of 2.5% in <a href=\"https://seekingalpha.com/pr/16907128-newell-brands-announces-second-quarter-2017-results\" target=\"_blank\">Q2</a>, driven by strong growth from Baby within the Live Segment, Writing within the Learn segment, Waddington within the Work Segment and Team Sports within the Play Segment.</li>     <li>Segment net sales: Live: $1.28B (+13.8%, Core sales: +0.2%); Learn: $1.01B (+10.9%,&nbsp;Core sales: +6.6%); Work: $737.7M (+14.1%,&nbsp;Core sales: +6.3%);&nbsp;Play:&nbsp;$782M (+14.2%,&nbsp;Core sales: -1.2%); Other:&nbsp;$245.9M (-50%,&nbsp;Core sales: -2.1%).</li>     <li>Northe America net sales down 4.8% to $3.18B</li>     <li>Normalized gross margin slipped 20 bps to 37%.</li>     <li>Normalized operating margin rate advanced 130 bps to 17.1%.</li>     <li><b>FY2017 Guidance</b>: Net sales: $14.8B to $15B (+11.5% to +13%); Core sales: +2.5% to +4%; Normalized EPS: $3 to $3.2; Share count: ~490M; Tax rate: 22% to 23%.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3285990\" data-linked=\"More on Newell Brands&#39; Q2\" data-tweet=\"$NWL - More on Newell Brands&#39; Q2 https://seekingalpha.com/news/3285990-on-newell-brands-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3285990-on-newell-brands-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285989\" data-ts=\"1501855996\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBB\" target=\"_blank\">CBB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285989-cincinnati-bellplus-13_6-after-q2-beats-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cincinnati Bell +13.6% after Q2 beats expectations</a></h4><ul>   <li>Cincinnati Bell (NYSE:<a href='https://seekingalpha.com/symbol/CBB' title='Cincinnati Bell Inc.'>CBB</a>) is still on the move, <font color='green'>up 13.6%</font> after posting <a href=\"https://seekingalpha.com/news/3285879-cincinnati-bell-beats-revenue\" target=\"_blank\">Q2 earnings</a> where it beat expectations thanks to revenue gains in Entertainment and Communications, which mitigated declines in legacy businesses.</li>    <li>Fioptics revenue in particular rose 24% Y/Y. That unit's Internet subscribers rose 22% (to 214,100), and video subs were up 13% (to 142,800).</li>    <li>Operating income dipped to $21M from $27M due to restructuring, severance and transaction charges, tied to initiatives CBB expects will save $10M annually.</li>    <li>EBITDA was up 1% to $77.2M, beating an expected $73.1M.</li>    <li>Revenue by segment, Entertainment and Communications: Data, $87.7M (up 1%); Voice, $67.1M (down 3%); Video, $37.2M (up 20%); Services and other, $9.4M (up 65%).</li>    <li>Revenue by segment, IT Services and Hardware: Professional Services, $23.5M (down 14%); Management and Monitoring, $5.1M (down 35%); Unified Communications, $11M (up 9%); Cloud Services, $11.6M (up 7%); Telecom and IT hardware, $44.8M (down 17%).</li>    <li>For the full year, it's reaffirming guidance for revenue of $1.2B (above consensus for $1.15B) and EBITDA of $295M (vs. expected $293.2M).</li>    <li><a href=\"https://seekingalpha.com/pr/16907173-cincinnati-bell-reports-second-quarter-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3285989\" data-linked=\"Cincinnati Bell +13.6% after Q2 beats expectations\" data-tweet=\"$CBB - Cincinnati Bell +13.6% after Q2 beats expectations https://seekingalpha.com/news/3285989-cincinnati-bellplus-13_6-after-q2-beats-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3285989-cincinnati-bellplus-13_6-after-q2-beats-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285980\" data-ts=\"1501855219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTHR\" target=\"_blank\">UTHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285980-takeover-rumor-du-jour-gilead-and-glaxo-eyeing-united-therapeutics-shares-up-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Takeover rumor du jour: Gilead and Glaxo eyeing United Therapeutics; shares up 9%</a></h4><ul><li>United Therapeutics (<a href='https://seekingalpha.com/symbol/UTHR' title='United Therapeutics Corporation'>UTHR</a> <font color='green'>+8.5%</font>) is up in early trading on rumors that Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='red'>-1.7%</font>) and GlaxoSmithKline (<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a> <font color='red'>-0.2%</font>) are eyeing the company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3285980\" data-linked=\"Takeover rumor du jour: Gilead and Glaxo eyeing United Therapeutics; shares up 9%\" data-tweet=\"$UTHR $UTHR $GILD - Takeover rumor du jour: Gilead and Glaxo eyeing United Therapeutics; shares up 9% https://seekingalpha.com/news/3285980-takeover-rumor-du-jour-gilead-and-glaxo-eyeing-united-therapeutics-shares-up-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3285980-takeover-rumor-du-jour-gilead-and-glaxo-eyeing-united-therapeutics-shares-up-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285977\" data-ts=\"1501854114\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVP\" target=\"_blank\">AVP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285977-deutsche-bank-sours-on-avon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank sours on Avon</a></h4><ul> <li>Deutsche Bank drops Avon Products (<a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a> <font color='red'>-1.5%</font>) to a Hold rating from Buy and slashes its price target to $3 from $5.</li> <li>The firm lacks conviction that Avon's second-half innovation initiatives will materialize as anticipated.</li> <li>A \"volatile\" macro environment in top markers is also seen as a risk for Avon.</li> <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3285977\" data-linked=\"Deutsche Bank sours on Avon\" data-tweet=\"$AVP - Deutsche Bank sours on Avon https://seekingalpha.com/news/3285977-deutsche-bank-sours-on-avon?source=tweet\" data-url=\"https://seekingalpha.com/news/3285977-deutsche-bank-sours-on-avon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285973\" data-ts=\"1501853396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBGL\" target=\"_blank\">SBGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285973-sibanye-goldplus-3_2-looks-to-restructure-gold-operations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sibanye Gold +3.2% as it looks to restructure gold operations</a></h4><ul>   <li>Sibanye Gold (NYSE:<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a>) is <font color='green'>up 3.2%</font> premarket as it undertakes a <a href=\"https://www.miningreview.com/news/sibanye-restructures-ensure-sustainability-gold-operations/\" target=\"_blank\">restructuring of its gold operations</a> amid ongoing losses at its Beatrix West and Cooke operations.</li>    <li>The company is starting S189 consultations after being unable to contain the losses. That will allow consideration of alternatives to closing the operations to avoid retrenchment.</li>    <li>&ldquo;The decision to commence with this restructuring process has not been taken lightly,&rdquo; says Sibanye CEO Neal Froneman. &ldquo;The long-term sustainability of the group as a whole is our primary focus and is necessary if we are to continue to deliver superior value to all of our stakeholders.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3285973\" data-linked=\"Sibanye Gold +3.2% as it looks to restructure gold operations\" data-tweet=\"$SBGL - Sibanye Gold +3.2% as it looks to restructure gold operations https://seekingalpha.com/news/3285973-sibanye-goldplus-3_2-looks-to-restructure-gold-operations?source=tweet\" data-url=\"https://seekingalpha.com/news/3285973-sibanye-goldplus-3_2-looks-to-restructure-gold-operations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285972\" data-ts=\"1501853122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTB\" target=\"_blank\">CTB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285972-margins-down-cooper-tire-rubber-in-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Margins down at Cooper Tire &amp; Rubber in Q2</a></h4><ul>     <li>Cooper Tire &amp; Rubber (NYSE:<a href='https://seekingalpha.com/symbol/CTB' title='Cooper Tire & Rubber Co.'>CTB</a>)&nbsp;reports unit volume fell 0.5% in <a href=\"https://seekingalpha.com/pr/16907150-cooper-tire-and-rubber-company-reports-second-quarter-2017-results\" target=\"_blank\">Q2</a>.</li>     <li>Americas tire sales down 6% to $615.4M due to 4.4% decline in unit volume, negative foreign currency impact.</li>     <li>International tire sales rose 22.4% to $151.37M.</li>     <li>Gross margin rate declined 610 bps to 18.2%.</li>     <li>SG&amp;A expense rate improved 160 bps to 7.8%.</li>     <li>Operating margin rate squeezed 440 bps to 10.4%.</li>     <li>Americas tire operating margin rate contracted 420 bps to 13.5%.</li>     <li><b>FY2017 Guidance</b>: Effective tax rate: 30% to 33%; Capex: $200M to $220M.</li><li>CTB&nbsp;<font color='green'>+0.14%</font>&nbsp;premarket.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3285972\" data-linked=\"Margins down at Cooper Tire &amp; Rubber in Q2\" data-tweet=\"$CTB - Margins down at Cooper Tire &amp; Rubber in Q2 https://seekingalpha.com/news/3285972-margins-down-cooper-tire-rubber-in-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3285972-margins-down-cooper-tire-rubber-in-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285971\" data-ts=\"1501853093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAGX\" target=\"_blank\">JAGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285971-jaguars-mytesi-orphan-drug-for-short-bowel-syndrome-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jaguar&#39;s Mytesi an Orphan Drug for short bowel syndrome; shares up 2% premarket</a></h4><ul><li>Jaguar Animal Health (NASDAQ:<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Animal Health, Inc.'>JAGX</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume on the news that the FDA designated Mytesi (crofelemer) an Orphan Drug for the treatment of short bowel syndrome.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280603-napo-pharma-announces-positive-data-hiv-diarrheal-product-mytesi-merger-partner-jaguar-animal\" target=\"_blank\">Napo Pharma announces positive data on HIV diarrheal product Mytesi; merger partner Jaguar Animal Health up 2%</a> (July 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3285971\" data-linked=\"Jaguar&#39;s Mytesi an Orphan Drug for short bowel syndrome; shares up 2% premarket\" data-tweet=\"$JAGX - Jaguar&#39;s Mytesi an Orphan Drug for short bowel syndrome; shares up 2% premarket https://seekingalpha.com/news/3285971-jaguars-mytesi-orphan-drug-for-short-bowel-syndrome-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3285971-jaguars-mytesi-orphan-drug-for-short-bowel-syndrome-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285970\" data-ts=\"1501852916\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/K\" target=\"_blank\">K</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285970-jpmorgan-positive-on-kellogg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan positive on Kellogg</a></h4><ul> <li>JPMorgan lifts Kellogg (NYSE:<a href='https://seekingalpha.com/symbol/K' title='Kellogg Company'>K</a>) to an Overweight rating after sizing up the company's profit-topping Q2.</li> <li>The firm <a href=\"https://www.reuters.com/article/us-kellogg-results-idUSKBN1AJ1QJ\" target=\"_blank\">likes</a> Kellogg's plan to use a warehouse distribution model instead of shipping directly to stores. The switch is expected to lower costs.</li> <li>JP assigns a price target of $78 to Kellogg.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285226-kellogg-beats-0_05-beats-revenue\" target=\"_blank\">Kellogg beats by $0.05, beats on revenue</a> (Aug. 3)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285385-kellogg-plus-5-percent-q2-beat\" target=\"_blank\">Kellogg +5% after Q2 beat</a> (Aug. 3)</li> <li>Shares of Kellogg are <font color='green'>up 1.26%</font> premarket to $71.25 vs. a 52-week trading range of $65.32 to $84.28.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3285970\" data-linked=\"JPMorgan positive on Kellogg\" data-tweet=\"$K - JPMorgan positive on Kellogg https://seekingalpha.com/news/3285970-jpmorgan-positive-on-kellogg?source=tweet\" data-url=\"https://seekingalpha.com/news/3285970-jpmorgan-positive-on-kellogg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285969\" data-ts=\"1501852902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLEX\" target=\"_blank\">LLEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285969-lillis-energyplus-3_6-names-linville-new-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lillis Energy +3.6% as it names Linville new CEO</a></h4><ul>   <li>Lillis Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a>) is <font color='green'>up 3.6%</font> premarket after naming James Linville its <a href=\"https://seekingalpha.com/pr/16907130-lilis-energy-names-james-linville-chief-executive-officer\" target=\"_blank\">chief executive officer</a>.</li>    <li>Linville is president of the exploration and development company; he's replacing Abraham Mirman, who's stepping down as CEO and as a director.</li>    <li>Linville's 30-year career has taken him to U.S. Energy Development Corp., American Energy Partners and Devon Energy.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3285969\" data-linked=\"Lillis Energy +3.6% as it names Linville new CEO\" data-tweet=\"$LLEX - Lillis Energy +3.6% as it names Linville new CEO https://seekingalpha.com/news/3285969-lillis-energyplus-3_6-names-linville-new-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3285969-lillis-energyplus-3_6-names-linville-new-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285967\" data-ts=\"1501852702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285967-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a> <font color='red'>-37%</font>.</li><li><a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>&nbsp;<font color='red'>-25%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3285477-applied-optoelectronics-beats-0_22-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/CFMS' title='ConforMIS'>CFMS</a>&nbsp;<font color='red'>-22%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3285609-conformis-beats-0_08-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/PI' title='Impinj, Inc.'>PI</a>&nbsp;<font color='red'>-21%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3285573-impinj-beats-0_04-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/NGVC' title='Natural Grocers'>NGVC</a>&nbsp;<font color='red'>-21%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3285606-natural-grocers-misses-0_09-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/IDN' title='Intellicheck Mobilisa, Inc.'>IDN</a> <font color='red'>-18%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16906558-intellicheck-announces-proposed-public-offering-common-stock\" target=\"_blank\">announcing</a> proposed public offering of common stock.</li><li><a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>&nbsp;<font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3285689-meet-group-beats-0_02-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/INFN' title='Infinera Corporation'>INFN</a>&nbsp;<font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3285528-infinera-beats-0_01-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/APLP' title='Archrock Partners, L.P.'>APLP</a>&nbsp;<font color='red'>-11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3285581-archrock-partners-launch-4m-unit-offering\" target=\"_blank\">announcing</a> a public offering of 4M common units.</li><li><a href='https://seekingalpha.com/symbol/TOPS' title='TOP Ships Inc.'>TOPS</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/MELI' title='MercadoLibre, Inc.'>MELI</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3285527-mercadolibre-misses-0_42-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3285508-viacom-beats-0_11-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/TRVG' title='Trivago'>TRVG</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3285873-trivago-reports-q2-results\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a>&nbsp;<font color='red'>-6%</font>&nbsp;on Heplisav-B <a href=\"https://seekingalpha.com/news/3285907-expected-fda-ok-dynavaxs-heplisav-b-postponed-three-months-finalize-details-post-marketing\" target=\"_blank\">postponed</a> three months to finalize details of post-marketing study.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3285967\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$EFII $AAOI $CFMS - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3285967-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3285967-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285966\" data-ts=\"1501852534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDLI\" target=\"_blank\">PDLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285966-pdl-bio-q2-top-line-up-585-non-gaap-earnings-up-166-cash-flow-down-35-shares-ahead-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PDL Bio Q2 top-line up 585%; non-GAAP earnings up 166%; cash flow down 35%; shares ahead 13% premarket</a></h4><ul><li>PDL BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a>) <a href=\"https://seekingalpha.com/pr/16906600-pdl-biopharma-announces-second-quarter-2017-financial-results\" target=\"_blank\">Q2 results</a> ($M): Revenues: 143.8 (+584.8%) due mainly from 83.7 from change in fair value of royalty rights related to Depomed <a href=\"http://investor.pdl.com/releasedetail.cfm?releaseid=798764\" target=\"_blank\">royalty asset</a>.</li><li>Received $34.6M in net cash royalties (+135.4%) mainly due to launch of generic Glumetza by Valeant Pharmaceuticals.</li><li>Net Income: 60.4 (+999%); Non-GAAP Net Income: 40.2 (+166.2%); EPS: 0.39 (+999%); CF Ops (6 mo.): 61.6 (-35.0%).</li><li>Shares are up&nbsp;<font color='green'>13%</font>&nbsp;premarket on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3285966\" data-linked=\"PDL Bio Q2 top-line up 585%; non-GAAP earnings up 166%; cash flow down 35%; shares ahead 13% premarket\" data-tweet=\"$PDLI - PDL Bio Q2 top-line up 585%; non-GAAP earnings up 166%; cash flow down 35%; shares ahead 13% premarket https://seekingalpha.com/news/3285966-pdl-bio-q2-top-line-up-585-non-gaap-earnings-up-166-cash-flow-down-35-shares-ahead-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3285966-pdl-bio-q2-top-line-up-585-non-gaap-earnings-up-166-cash-flow-down-35-shares-ahead-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285965\" data-ts=\"1501852527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KHC\" target=\"_blank\">KHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285965-soft-numbers-from-kraft-heinz-stoke-m-speculation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soft numbers from Kraft Heinz stoke M&amp;A speculation</a></h4><ul> <li>Kraft Heinz (NASDAQ:<a href='https://seekingalpha.com/symbol/KHC' title='The Kraft Heinz Company'>KHC</a>) slipped past Q2 profit estimates as a low tax rate factored in (23% vs. 30% a year ago). The underlying EBIT miss has Susquehanna boosting Kraft's M&amp;A profile.</li> <li>\"Given the slowing pace of EBITDA growth and net synergy realization at KHC, we are even more convinced now that another sizable M&amp;A deal is imminent,\" says analyst Pablo Zuanic.</li> <li>Zuanic adds in a 20% M&amp;A optionality premium (Buffett/3G) on Kraft vs. +10% prior. The current December 2018 price target on Neutral-rated Kraft is $85.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285483-kraft-heinz-reports-q2-results\" target=\"_blank\">Kraft Heinz reports Q2 results</a> (Aug. 3)</li> <li>KHC <font color='green'>+0.91%</font> premarket to $87.30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3285965\" data-linked=\"Soft numbers from Kraft Heinz stoke M&amp;A speculation\" data-tweet=\"$KHC - Soft numbers from Kraft Heinz stoke M&amp;A speculation https://seekingalpha.com/news/3285965-soft-numbers-from-kraft-heinz-stoke-m-speculation?source=tweet\" data-url=\"https://seekingalpha.com/news/3285965-soft-numbers-from-kraft-heinz-stoke-m-speculation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285963\" data-ts=\"1501851896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETSY\" target=\"_blank\">ETSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285963-etsy-soars-after-posting-strong-q2-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Etsy soars after posting strong Q2 growth</a></h4><ul> <li>Etsy (NASDAQ:<a href='https://seekingalpha.com/symbol/ETSY' title='Etsy, Inc.'>ETSY</a>) trades higher after posting 11% Y/Y growth in active sellers and 17% growth in active buyers during <a href=\"https://seekingalpha.com/pr/16906753-etsy-inc-reports-second-quarter-2017-financial-results\" target=\"_blank\">Q2</a>.</li> <li>As part of a cost structure review, Etsy says it identified ~$20M in 2017 expense reductions, which it expects to result in ~$35M in annualized cost savings.</li> <li>Looking ahead, Etsy sees 2017 GMS year-over-year growth of 12% to 14% and revenue growth of 18% to 20%. Adjusted EBITDA margin is seen falling in a range of 16% to 18%.</li> <li>ETSY <font color='green'>+8.17%</font> premarket to $14.70.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285643-etsy-beats-0_12-beats-revenue\" target=\"_blank\">Etsy beats by $0.12, beats on revenue</a> (Aug. 3)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3285963\" data-linked=\"Etsy soars after posting strong Q2 growth\" data-tweet=\"$ETSY - Etsy soars after posting strong Q2 growth https://seekingalpha.com/news/3285963-etsy-soars-after-posting-strong-q2-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3285963-etsy-soars-after-posting-strong-q2-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285958\" data-ts=\"1501851457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRNE\" target=\"_blank\">SRNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285958-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) initiated with Outperform rating and $7 (312% upside) price target by Oppenheimer. Shares up&nbsp;<font color='green'>9%</font>&nbsp;premarket.</li><li>Iovance Biotherapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/IOVA' title='Iovance Biotherapeutics, Inc.'>IOVA</a>) initiated with Outperform rating and $13 (141% upside)&nbsp;price target by Oppenheimer.</li><li>Global Blood Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a>) initiated with Outperform rating and $53 (95% upside) price target by Oppenheimer. Shares up&nbsp;<font color='green'>3%</font>&nbsp;premarket.</li><li>BioLineRx (NASDAQ:<a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a>) initiated with Outperform rating and $3 (186% upside) price target by Oppenheimer. Shares up&nbsp;<font color='green'>4%</font>&nbsp;premarket.</li><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) downgraded to Market Perform by Bernstein.</li><li>Spectranetics (NASDAQ:<a href='https://seekingalpha.com/symbol/SPNC' title='The Spectranetics Corporation'>SPNC</a>) downgraded to Hold by Stifel.</li></ul><div class=\"tiny-share-widget\" data-id=\"3285958\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$SRNE $SRNE $IOVA - Premarket analyst action - healthcare https://seekingalpha.com/news/3285958-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3285958-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285957\" data-ts=\"1501851239\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CZR\" target=\"_blank\">CZR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285957-caesars-entertainment-revenue-tops-billion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caesars Entertainment revenue tops a billion</a></h4><ul> <li>Caesars Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/CZR' title='Caesars Entertainment'>CZR</a>) narrowed its loss in <a href=\"https://seekingalpha.com/pr/16906587-caesars-entertainment-reports-financial-results-second-quarter-2017\" target=\"_blank\">Q2</a> on revenue of $1B. The company says it strong performance at Las Vegas properties was partially offset by weaker gaming volume in Baltimore and some bad luck at casinos.</li> <li>\"In the second quarter, stronger gaming fundamentals across most of our properties were offset by expected unfavorable year-over-year hold, primarily in baccarat, and the impact of more hotel rooms off the market for renovation,\" notes CEO Mark Frissora.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285478-caesars-entertainment-reports-q2-results\" target=\"_blank\">Caesars Entertainment reports Q2 results</a> (Aug. 3)</li> <li>Shares of Caesars are <font color='green'>up 6.56%</font> premarket to $13.00 on light volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3285957\" data-linked=\"Caesars Entertainment revenue tops a billion\" data-tweet=\"$CZR - Caesars Entertainment revenue tops a billion https://seekingalpha.com/news/3285957-caesars-entertainment-revenue-tops-billion?source=tweet\" data-url=\"https://seekingalpha.com/news/3285957-caesars-entertainment-revenue-tops-billion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285955\" data-ts=\"1501851119\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISR\" target=\"_blank\">ISR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285955-isoray-reports-preliminary-q4-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IsoRay reports preliminary Q4 revenue</a></h4><ul><li>IsoRay (NYSEMKT:<a href='https://seekingalpha.com/symbol/ISR' title='IsoRay, Inc.'>ISR</a>): Q4 Revenue of $1.37M (+22.3% Y/Y)</li><li>Shares <font color='green'>+3.89%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/16907248-isoray-announces-preliminary-fourth-quarter-f2017-revenue-1_37-million-22-percent-year-year\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3285955\" data-linked=\"IsoRay reports preliminary Q4 revenue\" data-tweet=\"$ISR - IsoRay reports preliminary Q4 revenue https://seekingalpha.com/news/3285955-isoray-reports-preliminary-q4-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3285955-isoray-reports-preliminary-q4-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285953\" data-ts=\"1501850968\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285953-tevas-travails-bearish-for-mylan-rbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva&#39;s travails bearish for Mylan - RBC</a></h4><ul><li>RBC's Randall Stanicky says Teva's (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) ugly Q2 and lowered guidance bodes ill for Mylan (NASDAQ:<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a>). \"We see near-term tactical downside trade into Q2,\" adding that a Q2 miss and forecast cut is likely when results are released on August 9.</li><li>Yesterday, Wells Fargo lowered its price target to $34.50 from $40.00, including assumptions for a potential $1B payout over the EpiPen misclassification and increased competition next year.</li><li>RBC also cut is rating on TEVA to underperform with a Street-low price target of $21 (from $37).</li><li>MYL is down&nbsp;<font color='red'>1%</font>&nbsp;premarket on light volume and TEVA is down&nbsp;<font color='red'>3%</font>&nbsp;on heavy volume.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3285953\" data-linked=\"Teva&#39;s travails bearish for Mylan - RBC\" data-tweet=\"$TEVA $TEVA $MYL - Teva&#39;s travails bearish for Mylan - RBC https://seekingalpha.com/news/3285953-tevas-travails-bearish-for-mylan-rbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3285953-tevas-travails-bearish-for-mylan-rbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285945\" data-ts=\"1501849955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285945-institutional-investor-sues-teva-to-recover-investment-losses-shares-down-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Institutional investor sues Teva to recover investment losses; shares down 1%</a></h4><ul><li>Stung by losses, Hedge fund Och Ziff files a lawsuit in a Connecticut district court against Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) accusing the company and certain ex-executives of intentionally misleading investors about the strength of the business, specifically attributing its performance to legitimate business practices rather than from illegal actions to inflate the prices of generic drugs.</li><li>Och Ziff intends to recover losses incurred between February 10, 2014 and November 2, 2016.</li><li>Shares are down&nbsp;<font color='red'>1%</font>&nbsp;premarket on increased volume.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3285945\" data-linked=\"Institutional investor sues Teva to recover investment losses; shares down 1%\" data-tweet=\"$TEVA - Institutional investor sues Teva to recover investment losses; shares down 1% https://seekingalpha.com/news/3285945-institutional-investor-sues-teva-to-recover-investment-losses-shares-down-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3285945-institutional-investor-sues-teva-to-recover-investment-losses-shares-down-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>69&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285938\" data-ts=\"1501849813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMC\" target=\"_blank\">AMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285938-amc-entertainment-moves-off-52-week-low-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMC Entertainment moves off 52-week low after earnings</a></h4><ul>     <li>AMC Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc'>AMC</a>) says a weaker than anticipated industry box office in the U.S. led to disappointing <a href=\"https://seekingalpha.com/pr/16907230-amc-entertainment-holdings-inc-announces-second-quarter-2017-results\" target=\"_blank\">Q2 results</a>. Higher film exhibition costs during the quarter also factored in.</li>     <li>Admissions revenues grew 63.8% to $1.58B (Carmike + Odeon acquisitions). Average U.S. ticket price rose 1.4% to $9.76.</li>     <li>Food and beverage revenues increased 58.2% to $772M. Food and beverage per patron increased 6.4% to $5.19.</li>     <li>Looking ahead, the company says it plans to reduce capex by $100M in the latter half of 2017 and an additional $100M in 2018, through a \"disciplined approach\" to cull lesser priority projects.</li>     <li>AMC Entertainment is <font color='green'>up 2.98%</font> premarket to $15.55. Shares hit a 52-week low of $14.80 yesterday.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3285911-amc-entertainment-misses-0_01-misses-revenue\" target=\"_blank\">AMC Entertainment misses by $0.01, misses on revenue</a> (Aug. 4)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3285938\" data-linked=\"AMC Entertainment moves off 52-week low after earnings\" data-tweet=\"$AMC - AMC Entertainment moves off 52-week low after earnings https://seekingalpha.com/news/3285938-amc-entertainment-moves-off-52-week-low-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3285938-amc-entertainment-moves-off-52-week-low-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285937\" data-ts=\"1501849802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LECO\" target=\"_blank\">LECO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285937-deutsche-upgrades-lincoln-electric\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche upgrades Lincoln Electric</a></h4><ul><li>Lincoln Electric (NASDAQ:<a href='https://seekingalpha.com/symbol/LECO' title='Lincoln Electric Holdings, Inc.'>LECO</a>) <font color='green'>+1%</font> premarket after Deutsche Bank <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Deutsche+Bank+Upgrades+Lincoln+Electric+%28LECO%29+to+Buy/13169325.html\" target=\"_blank\">raised</a> the stock to Buy from Hold, with a price target of $100.</li><li>\"Earnings growth should accelerate as the company is on a strong trajectory for the remainder of 2017 and into 2018,\" according to the firm, which believes strong cash flow generation should boost earnings growth beyond estimates.</li><li>Deutsche also thinks the global growth environment is improving which should offer a tailwind.</li></ul><div class=\"tiny-share-widget\" data-id=\"3285937\" data-linked=\"Deutsche upgrades Lincoln Electric\" data-tweet=\"$LECO - Deutsche upgrades Lincoln Electric https://seekingalpha.com/news/3285937-deutsche-upgrades-lincoln-electric?source=tweet\" data-url=\"https://seekingalpha.com/news/3285937-deutsche-upgrades-lincoln-electric\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285929\" data-ts=\"1501848982\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WING\" target=\"_blank\">WING</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285929-wingstopplus-6-after-earnings-dividend-initiation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wingstop +6% after earnings, dividend initiation</a></h4><ul> <li>Wingstop (NASDAQ:<a href='https://seekingalpha.com/symbol/WING' title='Wingstop, Inc.'>WING</a>) reports system-wide sales increased 14.4% in <a href=\"https://seekingalpha.com/pr/16906728-wingstop-inc-reports-fiscal-second-quarter-2017-financial-results\" target=\"_blank\">Q2</a> off a 16% higher store count.</li> <li>Same-store sales rose 2.0% at U.S. stores during the quarter.</li> <li>Higher bone-in chicken wing prices contributed to a 310 bps jump in cost of sales margin to 77.6% of sales.</li> <li>Wingstop initiates a $0.07 quarterly dividend to shareholders. The company also names Michael Skipworth as its CFO after the exec previously handled the role on an interim basis.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285679-wingstop-beats-0_03-beats-revenue\" target=\"_blank\">Wingstop beats by $0.03, beats on revenue</a> (Aug. 3)</li> <li>WING <font color='green'>+6.31%</font> premarket to $32.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3285929\" data-linked=\"Wingstop +6% after earnings, dividend initiation\" data-tweet=\"$WING - Wingstop +6% after earnings, dividend initiation https://seekingalpha.com/news/3285929-wingstopplus-6-after-earnings-dividend-initiation?source=tweet\" data-url=\"https://seekingalpha.com/news/3285929-wingstopplus-6-after-earnings-dividend-initiation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285911\" data-ts=\"1501848128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMC\" target=\"_blank\">AMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285911-amc-entertainment-misses-0_01-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMC Entertainment misses by $0.01, misses on revenue</a></h4><ul><li>AMC Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc'>AMC</a>): Q2 EPS of -$1.35 <font color='red'>misses by $0.01</font>.</li><li>Revenue of $1.2B (+57.1% Y/Y) <font color='red'>misses by $30M</font>.</li><li>Shares <font color='green'>+2.65%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16907230-amc-entertainment-holdings-inc-announces-second-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3285911\" data-linked=\"AMC Entertainment misses by $0.01, misses on revenue\" data-tweet=\"$AMC - AMC Entertainment misses by $0.01, misses on revenue https://seekingalpha.com/news/3285911-amc-entertainment-misses-0_01-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3285911-amc-entertainment-misses-0_01-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285907\" data-ts=\"1501847878\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVAX\" target=\"_blank\">DVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285907-expected-fda-ok-of-dynavaxs-heplisav-b-postponed-three-months-to-finalize-details-of-post\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Expected FDA OK of Dynavax&#39;s Heplisav-B postponed three months to finalize details of post-marketing study; shares down 5% premarket</a></h4><ul><li>Dynavax (NASDAQ:<a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a>) is down&nbsp;<font color='red'>5%</font>&nbsp;premarket on increased volume on the <a href=\"https://seekingalpha.com/pr/16906544-dynavax-provides-u-s-regulatory-update-heplisav-b-tm-following-fda-advisory-committee-meeting\" target=\"_blank\">news </a>that the FDA's action date to approve hepatitis B vaccine HEPLISAV-B has been extended three months to November 10 to allow sufficient time to finalize the details of a post-marketing study.</li><li>Specifically, the agency has requested a timeline for the final protocol submission, study completion and final report submission, the timeliness of patient accrual, time points for data review, measures to control potential biases between study arms and an updated statistical analysis plan.</li><li>The FDA's advisory committee voted 12 - 1 in favor of the safety data on July 28. The original action date was August 10.</li><li>The company says its plan to launch HEPLISAV-B in the U.S. in early 2018 remains unchanged.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283082-fda-ad-com-thumbs-dynavaxs-heplisav-b\" target=\"_blank\">FDA Ad Com thumbs up on Dynavax's Heplisav-B</a> (July 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3285907\" data-linked=\"Expected FDA OK of Dynavax&#39;s Heplisav-B postponed three months to finalize details of post-marketing study; shares down 5% premarket\" data-tweet=\"$DVAX - Expected FDA OK of Dynavax&#39;s Heplisav-B postponed three months to finalize details of post-marketing study; shares down 5% premarket https://seekingalpha.com/news/3285907-expected-fda-ok-of-dynavaxs-heplisav-b-postponed-three-months-to-finalize-details-of-post?source=tweet\" data-url=\"https://seekingalpha.com/news/3285907-expected-fda-ok-of-dynavaxs-heplisav-b-postponed-three-months-to-finalize-details-of-post\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285906\" data-ts=\"1501847796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPZM\" target=\"_blank\">EPZM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285906-epizyme-reports-q2-results-shares-ahead-17-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Epizyme reports Q2 results; shares ahead 17% premarket</a></h4><ul><li>Epizyme (<a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme'>EPZM</a>) <a href=\"https://seekingalpha.com/pr/16907119-epizyme-reports-second-quarter-2017-financial-results-clinical-business-progress\" target=\"_blank\">Q2 results</a>: Revenues: $10M; Operating Loss: ($28.5M) (-0.4%); Net Loss: ($28M) (-0.1%); Loss Per Share: ($0.48) (+2.0%); Quick Assets: $193M (-20.3%).</li><li><strong>2017 Guidance</strong>: The Company believes that its quick assets will be sufficient to fund the Company's planned operations into at least the Q3 2018.</li><li>Shares are up&nbsp;<font color='green'>17%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3285906\" data-linked=\"Epizyme reports Q2 results; shares ahead 17% premarket\" data-tweet=\"$EPZM - Epizyme reports Q2 results; shares ahead 17% premarket https://seekingalpha.com/news/3285906-epizyme-reports-q2-results-shares-ahead-17-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3285906-epizyme-reports-q2-results-shares-ahead-17-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285904\" data-ts=\"1501847699\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADP\" target=\"_blank\">ADP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285904-adp-ackman-seeking-control-of-company-shares-up-2_9-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ADP: Ackman seeking control of company; shares up 2.9% premarket</a></h4><ul><li>Pershing Square first contacted <a href='https://seekingalpha.com/symbol/ADP' title='Automatic Data Processing, Inc.'>ADP</a> on August 1, saying Bill Ackman owns 8% of the company - mostly in derivatives - and was requesting ADP extend the August 10 deadline for nominating directors by 30-45 days, with plans to nominate five, including himself. He also said he wants CEO Carlos Rodriguez replaced.</li><li>Open to constructive input from shareholders, ADP, however, notes it has a clearly defined board nomination process and won't be agreeing to Pershing Square's last minute request. It also notes a total shareholder return of 202% since Rodriguez became CEO six years ago - topping the S&amp;P 500's 128%, not to mention Pershing's 29%.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16907182-b-adp-b-says-pershing-square-capital-management-seeking-control-b-adp-b\" target=\"_blank\">Press Release</a></li><li>Shares&nbsp;<font color='green'>+2.9%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3285904\" data-linked=\"ADP: Ackman seeking control of company; shares up 2.9% premarket\" data-tweet=\"$ADP - ADP: Ackman seeking control of company; shares up 2.9% premarket https://seekingalpha.com/news/3285904-adp-ackman-seeking-control-of-company-shares-up-2_9-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3285904-adp-ackman-seeking-control-of-company-shares-up-2_9-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285900\" data-ts=\"1501847035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBPB\" target=\"_blank\">PBPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285900-margins-tighten-potbelly\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Margins tighten at Potbelly</a></h4><ul>     <li>Potbelly (NASDAQ:<a href='https://seekingalpha.com/symbol/PBPB' title='Potbelly Corporation'>PBPB</a>) reports comparable sales fell 4.9% in Q2.</li><li>Shop-level profit margin dropped to 19.2% of sales from 21.2% a year ago.</li>     <li>Looking ahead, Potbelly expects a mid-single digit decrease in company-operated comparable store sales and EPS of $0.30 to $0.33. A total of 45 to 50 new shop openings are anticipated.</li>     <li>\"We are testing a number of targeted initiatives to further build our brand and improve our traffic trends,\" says interim CEO Mike Coyne.</li><li>PBPB&nbsp;<font color='red'>-1.38%</font>&nbsp;premarket to $10.75.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3285900\" data-linked=\"Margins tighten at Potbelly\" data-tweet=\"$PBPB - Margins tighten at Potbelly https://seekingalpha.com/news/3285900-margins-tighten-potbelly?source=tweet\" data-url=\"https://seekingalpha.com/news/3285900-margins-tighten-potbelly\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285896\" data-ts=\"1501846678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NYMT\" target=\"_blank\">NYMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285896-q2-income-dips-new-york-mortgage-trust\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Q2 income dips at New York Mortgage Trust</a></h4><ul><li>Q2 net income of $11.1M or $0.10 per share vs. $16M and $0.14 in Q1. Dividend is $0.20.</li><li>Q2 book value per share of $6.02 down $0.06 from three months ago. Yesterday's close of $6.28 is a 4.3% premium to June 30 book.</li><li>Economic return for the quarter of $0.14, or 2.3% on book value.</li><li>Net interest margin of 312 basis points up from 270 points, mostly thanks to improved net margin in the distressed residential loan portfolio and increased average interest earning assets in the CMBS multifamily portfolio.</li><li><a href=\"http://www.nymtrust.com\" target=\"_blank\">Conference call at 9 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3285485-new-york-mortgage-trust-misses-0_05-misses-net-interest-income\" target=\"_blank\">New York Mortgage Trust misses by $0.05, misses on net interest income</a> (Aug. 3)</li><li>There's no premarket action, but <a href='https://seekingalpha.com/symbol/NYMT' title='New York Mortgage Trust, Inc.'>NYMT</a>&nbsp;<font color='red'>dipped 1.6%</font>&nbsp;in light after hours trade last night following the earnings release.</li></ul><div class=\"tiny-share-widget\" data-id=\"3285896\" data-linked=\"Q2 income dips at New York Mortgage Trust\" data-tweet=\"$NYMT - Q2 income dips at New York Mortgage Trust https://seekingalpha.com/news/3285896-q2-income-dips-new-york-mortgage-trust?source=tweet\" data-url=\"https://seekingalpha.com/news/3285896-q2-income-dips-new-york-mortgage-trust\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3285881\" data-ts=\"1501845811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CI\" target=\"_blank\">CI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3285881-cigna-q2-revenues-up-4-non-gaap-eps-up-47-updates-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CIGNA Q2 revenues up 4%; non-GAAP EPS up 47%; updates guidance</a></h4><ul><li>CIGNA (<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a>) <a href=\"https://seekingalpha.com/pr/16907104-cigna-reports-strong-second-quarter-2017-results-raises-outlook\" target=\"_blank\">Q2 results</a>: Revenues: $10,318M (+3.6%); Premiums and Fees: $7,179M (+3.4%).</li><li>Net Income: $813M (+59.4%); Non-GAAP Net Income: $750M (+45.6%); EPS: $3.15 (+59.9%); Non-GAAP EPS: $2.91 (+47.0%).</li><li><strong>2017 Guidance</strong>: Total Revenue Growth: 3 - 4%; Non-GAAP Net Income: $2.5 - 2.58B; Non-GAAP EPS: $9.75 - 10.05.</li></ul><div class=\"tiny-share-widget\" data-id=\"3285881\" data-linked=\"CIGNA Q2 revenues up 4%; non-GAAP EPS up 47%; updates guidance\" data-tweet=\"$CI - CIGNA Q2 revenues up 4%; non-GAAP EPS up 47%; updates guidance https://seekingalpha.com/news/3285881-cigna-q2-revenues-up-4-non-gaap-eps-up-47-updates-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3285881-cigna-q2-revenues-up-4-non-gaap-eps-up-47-updates-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM </div></div></li>","count":50,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}